Equity
Gilead Sciences·Balance Sheet Statement·8 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities and stockholders' equity | $53.6B | $54.5B | $59.0B | $56.4B | $55.7B | $58.5B | $59.0B | $56.3B |
| Total stockholders' equity | $18.3B | $18.5B | $19.3B | $19.2B | $19.7B | $21.5B | $22.7B | $23.5B |
| Retained earnings | $11.2B | $11.1B | $11.5B | $10.9B | $11.3B | $12.8B | $13.7B | $14.1B |
| Additional paid-in capital | $7.0B | $7.3B | $7.7B | $8.1B | $8.4B | $8.7B | $8.9B | $9.3B |
| Accumulated other comprehensive income (loss) | $93.0M | $73.0M | $132.0M | $92.0M | -$18.0M | $36.0M | $39.0M | $78.0M |
| Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M |
| AOCI - Foreign Currency Translation Adjustment, Net of Tax | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |